Retinoic acid syndrome after one dose of all-trans-retinoic acid

Journal of Oncology Pharmacy Practice

Volumn 10, Issue 3, 2004, Pages 149-154

  Battistella, Marisa ^a   Burry, Lisa D ^b   Seki, Jack T ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Acute promyelocytic; All trans retinoic acid; Dexamethasone; Leukaemia; Retinoic acid syndrome

Indexed keywords

CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IDARUBICIN; PREDNISONE; RETINOIC ACID;

ADULT; BODY WEIGHT DISORDER; CANCER REGRESSION; CASE REPORT; CONFUSION; DOSE RESPONSE; DRUG ACCUMULATION; DYSPNEA; FEMALE; FEVER; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEG EDEMA; LEUKOCYTOSIS; LUNG TOXICITY; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; WEIGHT GAIN;

EID: 6444226207     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155204jp128oa     Document Type: Review

References (40)

1. Tallman MS, Nabhan C, Feuser JH, Roe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-67.
2. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8: 1913-21.
3. Warrell RP, De The H, Wang ZY, Degops L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-89.
4. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
5. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997; 24: 92-102.
6. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33: 219-29.
7. Evans G, Grimwade D, Prentice HG, Simpson N. Central nervous system relapse in acute promyelocytic leukemia in patients treated with all-trans retinoic acid. Br J Haematol 1997; 98: 437-39.
8. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-53.
9. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 1993; 12: 1161-67.
10. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-215.
11. Chen SJ, Zelent A, Tong JH, Yu HQ, Wang ZY, Derre J, Berger R, Waxman S, Chen Z. Rearrangement of the retinoic acid receptor alpha and PLFZ genes resulting from t(11;17) (q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993; 91: 2260-67.
12. Huang M, Ye Y, Chen S, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
13. Warrell R, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93.
14. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I Clinical results. Blood 1990; 76: 1704-709.
15. Degos L, Chomienne C, Daniel MT, Berger R, Dombert H, Fenaux P, Castaigne S. Treatment of first relapse in acute promyelocytic leukemia with all transretinoic acid. Lancet 1990; 2: 1440-41.
16. Sun G, Ouyang R, Chen S, Juang GS, Zhang T. Follow up of 481 patients with APL after CR using ATRA. Chin J Hematol 1994; 15: 411-13.
17. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241-49.
18. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto J-J, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-200.
19. Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol MJ, González JD, Colomer D, Chillón C, Rivas C, Gómez T, Ribera JM, Bornstein R, Román J, Calasanz MJ, Arias J, Á lvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-21.
20. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Wood WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield KD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome results and prognostic factor analysis from Intergroup protocol 0129 [abstract]. Blood 1999; 94: 3086a.
21. Tallman MS. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia 1998; 12: S37-40.
22. Avvisati G, LoCoco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GEMEMA) Pilot Study. Blood 1996; 88: 1390-98.
23. Frankel SR, Eardly A, Lauwers G, Weiss M, Warrell RP. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-96.
24. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrell RP. All-trans retinoic acid for acute promyelocytic leukemia: result of the New York Study. Ann Intern Med 1994; 120: 278-86.
25. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-28.
26. De Botton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P, and the European APL Group. Incidence, clinical features, and outcomes of all trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-18.
27. De Gentile A, Toubert ME, Dubois C, Krawice J, Schlagetes MH, Balitrand N, Castaigne S, Degos L, Rain JD. Induction of high-affinity GM-CSF receptors during all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994; 8: 1758-62.
28. Dubois C, Schlageter MH, De Gentile A, et al. Modulation of II-8 and II-1b and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994; 8: 1750-57.
29. Dubois C, Schlageter MH, De Gentile A, Guidez F, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 1994; 83: 3264-70.
30. Larson R, Brown D, Sklar L. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997; 90: 2747-56.
31. Stadler M, Ganser A, Hoelzer K. Acute promyelocytic leukemia. N Engl J Med 1994; 330: 140-41.
32. Warrell RP, Degos L. Acute promyelocytic leukemia. N Engl J Med 1994; 330: 141.
33. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Luce Vegna M, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-21.
34. Avvisati G. AIDA Protocol: the Italian way of treating APL [abstract]. Br J Haematol 1998; 102: 593a.
35. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, François C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90-95.
36. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA, Warrell RP. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RARα isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-49.
37. Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience. Leukemia 1994; 8: 926-33.
38. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukemia Study Group. Leukemia 1995; 9: 774-78.
39. Firkin FC, Mathews JP, Bradstock KF, Wiley JS. A phase II study of all-trans retinoic acid (ATRA) with prednisone prophylaxis in the treatment of acute promyelocytic leukemia (APL)[abstract] Proc Am Soc Clin Oncol 1999; 94: 4225a.
40. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.